Propranolol and uraemic osteodystrophy.

Propranolol and uraemic osteodystrophy. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Propranolol and uraemic osteodystrophy. Abstract Text:

D Brancaccio,C Galmozzi,S Casati,D Rurale,S Belloli,A Aroldi,G Graziani,C Ponticelli,

Propranolol and uraemic osteodystrophy. Publishing Authors By Initials

D Brancaccio,C Galmozzi,S Casati,D Rurale,S Belloli,A Aroldi,G Graziani,C Ponticelli,

For similar male urogenital diseases: urologic diseases: kidney diseases: uremia research abstracts see: male urogenital diseases: urologic diseases: kidney diseases: uremia research

PUBMED ID PMID:

MEDLINE DATE:

Propranolol and uraemic osteodystrophy. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Proceedings of the European Dialysis and Transplan

VOLUME: 16

Page Numbers: 668-71

Journal Abbreviation:

ISSN: 0071-2736

DAY: 21

MONTH: 02

YEAR: 1979

Propranolol and uraemic osteodystrophy. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 355210

Propranolol and uraemic osteodystrophy. Keywords Mesh Terms:

KEYWORDS: Uremia

MESH TERMS: drug therapy

Chemical & Substance for Abstract: Propranolol and uraemic osteodystrophy. Information

Substance Name: Alkaline Phosphatase

Registry Number: EC 3.1.3.1

Grant and Affiliation Information for Propranolol and uraemic osteodystrophy.

AFFILIATION:

Country: ENGLAND

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Proc Eur Dial Transplant Assoc

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Propranolol and uraemic osteodystrophy Related Publications

• 'Y' connector system for prevention of peritonitis in CAPD: a controlled study.
• A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine.
• Acetohydroxamate in struvite stones: in vivo study.
• Acute kidney injury due to deferoxamine in a renal transplant patient.
• Can mTOR inhibitors reduce the risk of late kidney allograft failure?
• Dopamine-frusemide therapy in acute renal failure.
• Functions of Saccharomyces cerevisiae TFIIF during Transcription Start Site Utilization.
• High fluid intake or pharmacological therapy in recurrent stone former patients?
• Letter: Rosette inhibition test and cell-mediated immunity.
• Letter: T lymphocytes in kidney allograft recipients.
• New recommendations in the treatment of Gram-positive bacteraemia in dialysis patients.
• Propranolol and uraemic osteodystrophy.
• Role of proteinuria reduction in the progression of IgA nephropathy.
• Serological and genetic factors in early recurrence of IgA nephropathy after renal transplantation.
• The long-term outcome of 93 patients with proliferative lupus nephritis.
• Thiazide diuretics in renal hypercalciuria.
• Treatment of membranous nephropathy.
• Urinary acidification in renal allografts.
• [HCV-related liver disease in hemodialysis population: Clinical and biochemical characteristic.]